Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021

SELL
$5.58 - $7.04 $837 - $1,056
-150 Reduced 33.33%
300 $2,000
Q1 2021

Jun 17, 2021

SELL
$5.74 - $9.67 $13,753 - $23,169
-2,396 Reduced 84.19%
450 $3,000
Q1 2021

Jun 08, 2021

BUY
$5.74 - $9.67 $16,336 - $27,520
2,846 New
2,846 $3,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Prentice Wealth Management LLC Portfolio

Follow Prentice Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prentice Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prentice Wealth Management LLC with notifications on news.